|Net Assets||6.51 Bil|
- Last NAV update 5/24/2013 4:00 PM ET
|The investment seeks long-term capital appreciation. The fund normally invests at least 80% of its net assets (including any borrowings for investment purposes) in the common stocks of companies engaged in the research, development, production, or distribution of products or services related to health care, medicine, or the life sciences (collectively termed "health sciences"). While it can invest in companies of any size, the majority of fund assets are expected to be invested in large- and mid-capitalization companies. The fund may invest in foreign stocks and options in keeping with the fund's objectives.|
- Year to date performance as of 5/23/2013 8:00 PM ET
|Fund Family||T. Rowe Price|
|Fund Manager||Taymour Tamaddon|
|Minimum Initial Purchase||2,500.00|
|Minimum IRA Investment||1,000.00|
- * Annualized returns
- Performance as of 5/23/2013 8:00 PM ET
|Net Assets||6.51 Bil||504.68 Mil|
|Avg Market Cap||9.02 Bil||18.61 Bil|
|NAME||% NET ASSETS|
|Gilead Sciences Inc||5.06%|
|Alexion Pharmaceuticals, Inc.||4.83%|
|Valeant Pharmaceuticals International Inc||2.94%|
|Incyte Corp Ltd||1.98%|
|UnitedHealth Group Inc||1.92%|
|Regeneron Pharmaceuticals, Inc.||1.63%|
|Onyx Pharmaceuticals, Inc.||1.57%|
Copyright © 2013 Microsoft. All rights reserved.
Quotes are real-time for NASDAQ, NYSE and AMEX. See delay times for other exchanges.
Fundamental company data and historical chart data provided by Thomson Reuters (click for restrictions). Real-time quotes provided by BATS Exchange. Real-time index quotes and delayed quotes supplied by Interactive Data Real-Time Services. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations data provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by SIX Financial Information.